However, the clinical benefit of blocking PD1/PDL1 in combination with chemotherapy is currently restricted to a small subset of TNBC patients [21, 22, 29], likely because the majority of patients generate insufficient numbers of tumor-reactive lymphocytes with the necessary characteristics. The gene discussed is CD274; the disease is neoplasm.